BACKGROUND: Plasma renin is an important regulator of blood pressure (BP). Plasma renin activity (PRA) has been shown to correlate with variability in BP response to antihypertensive agents. We conducted a genome-wide association study to identify single-nucleotide polymorphisms (SNPs) associated with baseline PRA using data from the PEAR study (Pharmacogenomic Evaluation of Antihypertensive Responses).
H
ypertension is the most prevalent chronic cardiovascular disease, affecting ≈1 billion individuals worldwide, and ≈80 million adults in the United States. 1, 2 In addition, hypertension contributes to 50% of stroke and heart-related diseases and accounts for ≈18% of deaths worldwide. 3 These cardiovascular-related complications are largely avoidable with effective blood pressure (BP) management with antihypertensive medications, potentially resulting in a 35% to 40% reduction in stroke, a 15% to 25% reduction in myocardial infarction, and a 50% reduction in congestive heart failure. [4] [5] [6] Approximately, 54% of adults with hypertension have controlled BP (<140/90 mm Hg). 2 The interindividual variability in BP response to antihypertensive agents partially accounts for the suboptimal BP control rates. In addition to known clinical factors associated with BP response, including age, sex, and baseline BP, 7, 8 there is well-documented evidence that variability in components of the renin-angiotensin-aldosterone system (RAAS), including renin, is linked to differences in BP response to antihypertensive agents. [9] [10] [11] [12] Lower plasma renin activity (PRA) has been linked to better response to thiazide diuretics (hydrochlorothiazide), 9 ,11 whereas higher PRA has been associated with better BP response to RAASacting agents such as β-blockers (atenolol). 11 Collectively, these studies suggest that baseline PRA has reciprocal effects on BP response to antihypertensive drugs that inhibit versus stimulate activity of the RAAS (eg, diuretics versus β-blockers).
12 Accordingly, because β-blockers inhibit renin release, individuals with higher baseline PRA have better BP response to β-blockers; conversely, because diuretics stimulate renin release, individuals with higher baseline PRA do not respond as well to diuretics. 9, 11 Although several demographic and clinical factors, including age, race, and PRA, are predictive of antihypertensive drug response, 11 much of the remaining interindividual variability in BP response remains unexplained. There have been prior studies on the genetic influence of BP response [13] [14] [15] ; however, the genetic variability of PRA, an important clinical predictor of BP response, is understudied. A recently published genome-wide association study (GWAS) in normotensive individuals documented 2 independent loci in kininogen 1 (KNG1) and kallikrein B (KLKB1) showing genome-wide significant associations with components of RAAS including PRA, plasma renin concentrations, and aldosterone levels. 16 Yet, this phenotype has not been examined in hypertensive individuals, where the results could be used, along with other demographic, clinical, and genetic factors, to predict antihypertensive medication response.
Using a genome-wide association approach, we aimed to identify genetic variants associated with pretreatment or baseline PRA in hypertensive individuals. For those signals that met the genome-wide or suggestive level of significance, we tested the direction of association with BP response to either the β-blocker atenolol or the thiazide diuretic hydrochlorothiazide. We also assessed for potential function through gene expression differences by genotype and tested for replication of the top PRA signal in an independent sample.
METHODS
The genome-wide association data and phenotypes for the PEAR study (Pharmacogenomic Evaluation of Antihypertensive Responses) are available on dbGaP (The database of Genotypes and Phenotypes, phs000649.v1.p1).
CLINICAL PERSPECTIVE
Only about half of adults with hypertension have controlled blood pressure (BP), which is due in part to interindividual variability in BP response to antihypertensive agents. In addition to known clinical factors, components of the renin-angiotensinaldosterone system, including renin, have been associated with these differences in BP response. To identify biomarkers that could be used to predict antihypertensive response, we conducted a genome-wide association study with plasma renin activity (PRA) in hypertensive individuals. The top signals were prioritized and validated based on BP response to a β-blocker and thiazide diuretic, gene expression differences by genotype, and replication in an independent sample. Our prioritization and validation strategy identified the SNN-TXNDC11 gene region. The G allele of rs3784921 was associated with higher baseline PRA and reduced systolic BP response to hydrochlorothiazide. In cisexpression quantitative trait locus analysis, T allele carriers at rs3784921 showed significantly higher expression for TXNDC11 and SNN compared with GG homozygotes. A proxy single-nucleotide polymorphism, rs1802409, replicated the PRA signal in an independent sample, and on meta-analysis, the region showed a stronger association. Other signals associated with PRA and BP response to a β-blocker or thiazide diuretic were identified in CHD9, XIRP2, and GHR. The regions identified in this study may help personalize selection of antihypertensive agents. These single-nucleotide polymorphisms and regions should be tested in other independent cohorts to validate their role in PRA and BP response. In addition, investigation into the functional role of these genes may provide further insight into the BP response mechanisms associated with β-blockers and thiazide diuretics. 
Study Design and Participants

Pharmacogenomic Evaluation of Antihypertensive Responses
The PEAR study was a prospective, multicenter, randomized, open-label clinical trial in mild-to-moderate hypertensive participants. Additional details on the PEAR trial have been reported previously. 17 In brief, PEAR enrolled 768 men and women, aged 17 to 65 years with uncomplicated primary hypertension. After an average washout period of 4 weeks, participants were randomized to either atenolol 50 mg or hydrochlorothiazide 12.5 mg once daily monotherapy for 3 weeks, followed by dose titration to atenolol 100 mg or hydrochlorothiazide 25 mg once daily if BP remained >120/70 mm Hg for an additional 6 weeks. After the monotherapy period, drug from the other treatment arm was added if BP remained above goal, followed by a similar dose titration protocol, for another 6 to 9 weeks of treatment.
Pharmacogenomic Evaluation of Antihypertensive Responses-2
The PEAR-2 study (URL: https://www.clinicaltrials.gov. Unique identifier: NCT01203852) was a prospective, randomized, multicenter, sequential, open-label clinical trial in mild-tomoderate hypertensive participants. During PEAR-2, participants were initiated on either the β-blocker metoprolol 50 mg or the thiazide-like diuretic chlorthalidone 15 mg twice daily for 2 weeks, followed by dose titration to metoprolol 100 mg or chlorthalidone 25 mg twice daily for an additional 6 weeks if BP remained >120/70 mm Hg. After a minimum 4-week washout period, monotherapy with the other drug followed by a similar dose titration protocol was conducted for another 6 to 8 weeks of treatment. Inclusion criteria and additional details on the PEAR-2 trial have been previously published. 18 All PEAR and PEAR-2 study participants provided written informed consent. Both studies were approved by the Institutional Review Boards at the participating clinical trial sites (University of Florida in Gainesville, FL; Mayo Clinic in Rochester, MN; and Emory University in Atlanta, GA) and were conducted in accordance with the principles of the Declaration of Helsinki and the US Code of the Federal Regulations for Protection of Human Subjects.
Determination of PRA
Pharmacogenomic Evaluation of Antihypertensive Responses
Laboratory values including PRA were acquired at baseline, after monotherapy, and after combination therapy. 17 PRA was measured by radioimmunoassay using reagents purchased from DiaSorin (Stillwater, MN), a 3-hour incubation period for angiotensin I generation, and the method published by Sealey. 19 All measurements were conducted at a central laboratory at the Mayo Clinic, Rochester, MN. Samples were tested in duplicate or triplicate, and participants' mean values were used for analysis.
Pharmacogenomic Evaluation of Antihypertensive Responses-2
Laboratory values, including PRA, were acquired at baseline before initiation of each drug treatment, as well as after each monotherapy period. PRA during PEAR-2 was determined at the Mayo Clinic using the same methods and reagents as during PEAR.
BP Phenotype
During PEAR, BP measurements were collected at baseline, after monotherapy, and after combination therapy through 3 different methods: office, home, and ambulatory, as previously described. 17 A composite-weighted average of BP response through these different methods (office, home, ambulatory daytime, and ambulatory nighttime) was previously calculated based on row sums of the inverse of the intermethod covariance matrices. 20 The composite-weighted average BP response had a higher signal:noise ratio compared with any BP measurement method individually. 20 The composite BP response measurement is considered the most precise BP response phenotype available in PEAR and was selected for analysis. In its calculation, the composite BP response measurement is already adjusted for age, sex, and baseline BP. The BP phenotype from PEAR-2 was not used for this study.
Single-Nucleotide Polymorphism Genotyping and Quality Control
Pharmacogenomic Evaluation of Antihypertensive Responses
Participants' genomic DNA was genotyped for >1 million single-nucleotide polymorphisms (SNPs) using the Illumina Human Omni1-Quad BeadChip (Illumina, San Diego, CA). The quality control steps used have been previously published. 13 Principal components for ancestry were identified using the EIGENSTRAT method. 21 Genotype imputation was performed using MaCH (version 1.0.16) and HapMap III reference panels. 22 SNPs with minor allele frequency <3% were excluded. Additionally, SNPs with an imputation quality r 2 <0.3 were excluded. After imputation and quality control, the final genetic data set consisted of 758 samples (n=461 white, n=297 black).
Pharmacogenomic Evaluation of Antihypertensive Responses-2
Participants' genomic DNA was genotyped for >2.5 million SNPs using the Illumina Human Omni2.5S BeadChip (Illumina, San Diego, CA). Quality control and principal component analysis during PEAR-2 used the same methods as PEAR. For the replication study, only directly typed SNP data were used. Genotype data were available on 303 samples (n=150 white, n=153 black).
GWAS and SNP Prioritization
Multiple linear regression was performed using PLINK 23 to test the association between genotype dosage and baseline logtransformed PRA in PEAR whites and blacks separately, adjusting for age, sex, and ancestry-specific principal components 1 and 2, under an additive genetic model. Of the top GWAS SNPs associated with baseline PRA (P<1×10 −5 ), we selected 1 SNP per gene region to move forward for drug response prioritization ( Figure 1, step 1 ). During the drug response prioritization step, we assessed whether any of the top SNPs were associated with BP response in the expected direction ( Figure 1 , step 2). In this step, SNPs were tested for association with the composite BP response (systolic BP [SBP] and diastolic BP) to atenolol or hydrochlorothiazide monotherapy in PEAR, additionally adjusting for principal components 1 and 2 for ancestry. We expected that SNPs associated with higher baseline PRA would be associated with better BP response to atenolol or reduced response to hydrochlorothiazide. Conversely, we expected that SNPs associated with lower baseline PRA would be associated with better BP response to hydrochlorothiazide or reduced response to atenolol. 11 The significance threshold for the drug response prioritization step was a 1-sided P<0.05, as we had a 1-sided hypothesis for each SNP. All analyses were done separately by ancestry because of race-based differences in allele frequencies, linkage disequilibrium, 24 and antihypertensive drug response. 9, 10, 25 Haploreg and Genotype-Tissue Expression project were used to assess the potential functional consequences of the SNPs and gene regions that passed the drug response prioritization step. 26, 27 Stepwise linear regression was conducted in SAS v. 9.4, by forcing all covariates into the model, to determine the partial R 2 or variability of the traits that was explained by the top SNP (rs3784921).
Gene Expression Analysis for Functional Prioritization
Gene expression analysis by genotype was performed for the top genes and top SNPs associated with PRA that passed the drug response prioritization step, namely, whether the SNP was associated with BP response in the expected direction ( Figure 1, step 3) . We used RNA sequencing data from 50 PEAR white participants, who were selected based on the extreme quartiles of BP response after hydrochlorothiazide treatment: 25 poor BP responders and 25 good BP responders. RNA was extracted from whole blood samples collected at baseline, using the PAXgene Blood RNA kit IVD (Qiagen, Valencia, CA). Libraries were prepared after poly(A) mRNA selection and strand-specific protocol. 28 DNA clusters were generated using the Illumina cluster station, followed by 100 cycles of paired-end sequencing on the Illumina HiSeq 2000. Quality per base pair was checked using FastQC. One hundred base pair paired-end RNA sequencing reads were mapped to the human genome (hg19) using TopHat2, 29 and read duplicates were removed using Picard (http://picard.sourceforge. net) MarkDuplicates option. Transcript assembly and statistical analysis were conducted with Cufflink/Cuffdiff. 29 Gene expression levels are reported here in fragments per kilobase per million reads. Considering reads mapped to exonic regions of SNN, TXNDC11, and CHD9, expression quantitative trait locus (eQTL) analyses were performed with genotype calls for rs3784921 (SNN), rs3784921 (TXNDC11), and rs7184292 (CHD9) in R, fitting linear regression models using additive or dominant effects. GHR and XIRP2 were excluded from analysis as they were expressed at extremely low levels in the data set. The P value for significance was set at 0.017 (0.05/3 tests) for the eQTL analysis.
Replication of the Top Signal(s)
SNPs from the gene regions that passed the drug response prioritization step ( Figure 1, step 2 ) and the functional evidence prioritization step (Figure 1, step 3) were moved forward for replication of the baseline PRA signal in an independent sample of whites from the PEAR-2 study (Figure 1,  step 4) . From the SNN-TXNDC11 region, only rs1802409 was available in the replication data set; the other SNPs were not included on the Illumina Human Omni2.5S BeadChip. As the 3 SNPs in the SNN-TXNDC11 region are in high linkage disequilibrium (r 2 =0.98-1.00; D'=1), rs1802409 served as a proxy for the region. Multiple linear regression was performed using PLINK 23 to test the association between genotype and baseline log-transformed PRA in PEAR-2 whites, adjusting for age, sex, and principal component 1 for ancestry, under an additive genetic model. A 1-sided significance threshold of P<0.05 was selected, as only 1 SNP was tested, and we had a 1-sided hypothesis. The results from the discovery and replication were combined in meta-analysis using METAL under a fixed-effects model, weighting by sample size. RNA sequencing data were used to conduct association of top SNPs with gene expression (eQTL analysis); PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) data were used for discovery GWAS analysis; PEAR-2 was used for independent study replication of top SNPs. BP indicates blood pressure; eQTL, expression quantitative trait locus; GWAS, genome-wide association study; and PRA, plasma renin activity. 
RESULTS
Baseline demographic and clinical characteristics of PEAR study participants are presented in Table 1 . A total of 758 study participants were available for analysis after quality control procedures; 61% were white and 39% were black. Baseline PRA was lower among blacks than among whites, with an average baseline PRA of 0.59±0.68 ng mL ) also showed association with BP response to atenolol or hydrochlorothiazide in the expected direction (P<0.05) during the prioritization stage. All 8 SNPs were in Hardy-Weinberg Equilibrium (P>0.01). Table 2 and Table I in the Data Supplement show the top SNPs from each gene region in white and black participants, respectively; Figure 2 shows the flow of the results.
Three SNPs in the SNN-TXNDC11 gene region at 16p13.13 were associated with baseline PRA at a suggestive level (P<1.0×10 −5 ). Of the 3 SNPs, we selected the top SNP rs3784921 to move forward to prioritization. This SNP passed the drug response prioritization step through association with SBP response to hydrochlorothiazide in whites, where the G allele of rs3784921 was associated with higher baseline PRA (β=0.47; P=2.09×10 −6 ; Table 2; Figure 3A ) and reduced SBP response to hydrochlorothiazide (β=2.97; 1-sided P=0.006; Table 2 ; Figure 3B) , with a mean baseline PRA of 0.14, 0.38, and 0.97 ng mL −1 h −1 and a mean hydrochlorothiazide-induced SBP change of −15.4, −11.3, and −7.9 mm Hg for the TT, TG, and GG genotypes, respectively. Within whites in PEAR-1, rs3784921 accounted for 3.8% of the variability in baseline renin. In addition, rs3784921 accounted for 1.4% and 1.1% of the variability of SBP response to hydrochlorothiazide and diastolic BP response to hydrochlorothiazide, respectively.
In the cis-eQTL analysis, rs3784921 in the SNN-TXNDC11 region, which was associated with baseline PRA among PEAR whites, was significantly associated with baseline expression of TXNDC11. T allele carriers showed significantly higher fragments per kilobase per million reads values for TXNDC11 and SNN compared with GG homozygotes (r 2 =0.150; P=0.007; Figure 3C ). No difference in expression by genotype was observed for the other genes.
Furthermore, a proxy SNP, rs1802409, in high linkage disequilibrium with the top SNP rs3784921 in TXNDC11, replicated in PEAR-2 whites for association with baseline PRA. The C allele of rs1802409 was associated with higher baseline PRA (β=0.15; 1-sided P=0.038), and the mean baseline PRA was 1.01 and 1.35 ng mL −1 h −1 for the AC and CC genotypes, respectively ( Figure 3D ). There were no individuals with the AA genotype in PEAR-2. Meta-analysis between rs3784921 from PEAR and rs1802409 from PEAR-2 showed a stronger association (meta P=2.63×10 −7 ). Demographic characteristics of PEAR-2 whites are broadly similar to those of PEAR whites. The demographics of the 150 PEAR-2 whites included in the replication study are provided in Table II in the Data Supplement. In whites, the SNP rs7184292 near CHD9 at 16q12.2 was associated with baseline PRA at a genome-wide significant level. The A allele of rs7184292 was associated with higher baseline PRA (β=0.30; P=4.05×10 −9 ; Table 2; Figure 4A ) and better SBP response to atenolol (β=−1.68; 1-sided P=0.015; Table 2 ; Figure 4B) , with a mean baseline PRA of 2.15, 0.87, and 0.51 ng mL −1 h −1 and a mean atenolol-induced SBP change of −14.7, −13.1, and −11.1 mm Hg for the AA, AG, and GG genotypes, respectively. We did not find additional functional evidence for this SNP.
In blacks, the C allele of rs7606603 in XIRP2, at 2q24.3, was associated with lower baseline PRA (β=−0.42; P=1.71×10 −7 ; Table I ; Table I 
DISCUSSION
In this study, among a cohort of uncomplicated hypertensives, we identified SNPs associated with baseline PRA through a GWAS and prioritized these signals through association with BP response to 2 mechanistically different antihypertensive agents in whites and blacks. We then prioritized the top SNPs based on functional evidence, followed by replication in an independent study. To our knowledge, this is the first study to identify PRA-associated SNPs with a BP response prioritization method, with additional functional evidence prioritization and replication. Using this approach, we found 1 region in whites, SNN-TXNDC11, that was associated with baseline PRA in PEAR at the suggestive level (P=2.09×10 −6 ), showed association with reduced BP response to hydrochlorothiazide, showed association with expression of TXNDC11 as an eQTL, and replicated in an independent study with baseline PRA. In addition, we found another region in whites that passed SNP prioritization, 16q12.2-CHD9, which was associated with baseline PRA at a genome-wide significant level and also showed association with BP response to atenolol in the expected direction. In blacks, we found 2 regions, XIRP2 and GHR, with suggestive evidence of association with baseline PRA and associations with BP response.
The top region from our study spans 2 genes, SNN and TXNDC11, and is located at chromosome 16p13. 13 . SNN encodes stannin, a highly conserved protein localized to the mitochondria and endoplasmic reticulum membranes. 31 The role of SNN in renin levels and BP regulation through the RAAS is unclear. SNN is upregulated in endothelial cells in response to the N=461 (baseline PRA), N=233 (atenolol BP response), N=228 (HCTZ BP response). A1 indicates reference allele; BP, blood pressure; CHR, chromosome, location based on NCBI build 36; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; PEAR, Pharmacogenomic Evaluation of Antihypertensive Responses; PRA, plasma renin activity; SBP, systolic blood pressure; and SNP, single-nucleotide polymorphism.
*P value is 1-sided, based on the 1-sided prioritization hypothesis. 
PEAR (Pharmacogenomic Evaluation of Antihypertensive
Responses) data were used for discovery GWAS analysis; PEAR-2 was used for independent study replication of top single-nucleotide polymorphisms (SNPs). ATEN indicates atenolol; BP, blood pressure; HCTZ, hydrochlorothiazide; and PRA: plasma renin activity.
inflammatory cytokine TNF (tumor necrosis factor)-α, suggesting that SNN may be involved in the inflammatory process leading to atherosclerosis. 32 TXNDC11 (also known as EFP1) encodes thioredoxin domain-containing protein 11. The protein primarily exists in the endoplasmic reticulum and was recently identified as being important for proper endoplasmic reticulum-associated degradation of Major Histocompatibility Complex class I molecules. 33 Using our baseline RNA sequencing data among PEAR whites, we identified rs3784921 as an eQTL for TXNDC11. Data from Haploreg show that rs3784921 is also an eQTL for SNN in whole blood. 27 Furthermore, we were able to replicate the association with baseline PRA and the proxy SNP, rs1802409, in an independent study, PEAR-2. Together, these data suggest that there may be a functional connection between SNPs in this region, SNN and TXNDC11, and renin, the RAAS, and BP regulation, though the basis for this remains unclear. As the results for the PEAR/ PEAR-2 meta-analysis were below the genome-wide significance threshold (meta P=2.63×10 −7 ), further validation of this region is needed.
Our study also identified a region at chromosome 16q12.2 that included 2 genome-wide significant SNPs (rs7184292 and rs7201620, located 169 kb 3′ of the gene CHD9, which encodes chromodomain helicase DNA binding protein 9). These SNPs have expected regulatory function, show evidence of regulatory chromatin states in DNAse and enhancer histone marks in the brain, and are predicted to alter regulatory motifs. 27 In addition, there have been prior studies on CHD9, the closest gene to the associated region. A previous GWAS showed that a variant in CHD9 is associated with plasma fibrinogen concentration. 34 Although the role of CHD9 in the cardiovascular system, particularly the RAAS and BP regulation, is unclear, CHD9 is a transcriptional activator of PPAR (peroxisome proliferator-activated receptor)-α, a nuclear receptor that is widely expressed in the vasculature among other tissues and may be involved in BP regulation. [35] [36] [37] [38] [39] In blacks, we identified 2 regions with suggestive evidence of association with baseline PRA and signals with BP response. rs7606603 in XIRP2, also known as CMYA3, was associated with baseline PRA and BP response to atenolol. XIRP2 is a member of the cardi- ac and skeletal muscle-specific actin-binding Xin gene family and encodes cardiomyopathy-associated protein 3, which is involved in protecting actin filaments from depolymerization. XIRP2 interacts with the RAAS and kallikrein-kininogen system but possibly more so as a mediator of angiotensin II-induced myocardial damage. 40, 41 Other studies have found that angiotensin II increases XIRP2 expression by inducing transcription factor myocyte enhancer factor 2A or MEF2A. 40, 42 The connections between XIRP2, the RAAS, and the kallikrein-kininogen system are interesting given that a recent GWAS among normotensive individuals identified associations between renin activity and SNPs in the kininogen 1 and kallikrein B genes, which are both involved in the production of bradykinin. 16 Further, the second region identified among blacks is on chromosome 5, with the nearest coding gene, GHR, located ≈230 kb 3′ of rs16872401. GHR is a member of the type I cytokine receptor family and encodes a transmembrane receptor that binds growth hormone. Studies in mice overexpressing growth hormone and individuals with acromegaly have suggested that growth hormone, as well as growth hormone receptor activation, may contribute to hypertension and cardiovascular diseases through interaction with RAAS. [43] [44] [45] [46] When examining the top SNPs in the other race group, we were unable to replicate our findings. However, this may be driven by the differences in allele frequencies between the 2 race groups for the top SNPs (differences range between 16% and 24%). We did still observe a consistent direction of effect for rs3784921 in the SNN-TXNDC11 region in blacks.
Our study has a few limitations. We have a relatively small sample size. However, through careful measurements of PRA, prioritization based on BP response to 2 mechanistically different antihypertensive drugs, assessment of functional evidence, and replication, we were able to identify 1 region: SNN-TXNDC11. In addition, through BP response prioritization, we found a genome-wide significant locus (CHD9) and 2 other suggestive loci (XIRP2 and GHR). All of these loci were prioritized through directionally specific associations with BP response to a β-blocker (atenolol) or thiazide diuretic (hydrochlorothiazide). This method relies on the premise that genetic variants with a positive correlation with baseline PRA will have increased response to atenolol and decreased response to hydrochlorothiazide. Conversely, we hypothesized that variants associated with lower baseline PRA will be associated with greater BP response to hydrochlorothiazide and a lower response to atenolol. Although there is literature evidence to support our hypothesis, including prior studies in the PEAR population, 9, 11 this direct method has never been tested before. As we only focused on SNPs that met the requirements of our prioritization scheme, we could have missed other signals that impact PRA. In addition, none of the variants were associated with BP response to both a β-blocker (atenolol) and thiazide diuretic (hydrochlorothiazide), in the expected directions. This may be because of our small sample size, or the fact that BP response can be influenced by several factors. [7] [8] [9] [10] [11] [12] There are also other factors, such as urine sodium excretion that could impact PRA. However, when we added baseline urine sodium as a covariate to our linear regression model, the magnitudes of association for our top signals were broadly unchanged (data not shown). In addition, differences in the mean doses of each antihypertensive agent by genotype could confound the results from our BP prioritization step. Yet, when we examined mean dose by genotype, there were no significant differences seen for 3 out of 4 of our top SNPs, with only rs7184292 showing a significantly lower dose in GG homozygotes (Table IV in the Data Supplement). We did not observe signals in the regions previously associated with PRA in normotensive individuals. 16 It is possible that differences in the underlying genetic architecture between normotensive and hypertensive individuals, one of which may manifest as altered RAAS signaling for hypertensive individuals, may account for the dissimilar PRA signals across the 2 studies. Finally, although we have adjusted for multiple comparisons in the current analyses, we have previously published other studies in these cohorts with other phenotypes including BP response. [13] [14] [15] As we only used BP response to prioritize the PRA signals, we observed no overlap between the genes identified in this study, and those identified previously. [13] [14] [15] In conclusion, we used a genome-wide association approach to identify SNPs associated with baseline PRA, prioritized these signals by testing for their expected direction of association with BP response to 2 mechanistically different antihypertensive drug classes, a β-blocker and a thiazide diuretic, and then further assessed these regions for functional evidence with an eQTL analysis, followed by replication. Using this method, we identified 1 region that showed functional evidence and replicated in an independent study (SNN-TXNDC11), 1 genome-wide significant region that passed the prioritization stage (CHD9), and 2 other suggestive loci in blacks that passed the prioritization stage (XIRP2, GHR). Further validation and investigation into the functional roles of the top loci are needed to confirm these findings.
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